Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Inclusion Criteria: * Metastatic breast cancer HER2-/RH+ * Progression after hormonotherapy * Treated by taxanes, anthracyclines, capecitabine and eribulin * Treated by everolimus * ECOG ≤ 2 * Hematological Function: neutrophiles ≥ 1,5 x 109 / L, hemoglobin ≥ 9 g / dL, plaques ≥ 100 x 109 / L * Hepatic function: albumin ≥ 2,5 g / dl, bilirubin serum ≤ 2 x N (superior border of the standard) (unless disease of Gilbert), transaminases ≥ 3 x N * Renal Function: serum creatinine ≤ 1,5 mg / dL or clearance of the creatinine ≥ 40 mL / min * Estimated Life expectancy ≥ 3 months Exclusion Criteria: * Hypersensitivity known about one of the constituents of the estramustine phosphates * Preliminary Treatment by estramustine phosphates * Brain Metastases * Patients not being under effective contraception * Minor, pregnant or lactating Patients * Patients not previously treated by everolimus * Transaminases \> 3xN * Other concomitant anticancer treatment less than 1 month before the inclusion * Digestive function: malabsorption * History of other cancer in the previous 5 years (other than squamous-cell epithelioma or totally resected in situ carcinoma) * Active Thrombo-phlebitis * Risk thromboembolic known, * Unchecked cardiovascular Pathology * Grave hepatic Affection